IL6 and COVID-19: Actually, PCSK9 inhibition effectively reduced the primary endpoint of death or need for intubation, as well as IL-6 levels in severe COVID-19 compared to placebo; moreover, patients with more severe inflammation at the time of randomization had better survival with PCSK9 inhibition than placebo, indicating that the intensity of inflammation may drive therapeutic benefits [77].